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INTRODUCTION
Pregnancy and coronavirus disease-2019 (COVID-19) share 
several common features: both are multisystem disorders, 
may present with breathlessness, are associated with hyper-
coagulability and frequently cause significant anxiety in both the 
patient and those around them – see Table I for abbreviations. 
Pregnancy represents a state of partial immune suppression, 
with pregnant women more vulnerable to viral infections, and 
morbidity and mortality higher even with seasonal influenza. In 
addition to influenza, infection with H1N1, Zika, Middle East 
respiratory syndrome (MERS) and severe acute respiratory 
distress syndrome (SARS) during pregnancy may have catas-
trophic effects on both mother and baby: pregnant women 
have worse outcomes, including higher mortality rates and 
higher risk of fetal loss, preterm birth and growth restriction. 
For MERS and SARS, case fatality rates are as high as 23% - 
25%.(1,2) Zika virus infection, on the other hand, affects cerebral 
and ocular development in utero, while maternal outcomes are 
largely unaltered.(3) Given its aetiological agent, severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) is a related 
virus and there has been concern that the COVID-19 epidemic 
may have serious consequences for pregnant women and 
their babies. However, these concerns have not been borne 
out in clinical practice and have not stood up to epidemio-
logical scrutiny. 
Interim guidance has been issued by the World Health 
Organization (WHO) and Centers for Disease Control and 
Prevention (CDC) on managing COVID-19, which include 
some recommendations specific to pregnant women, mostly 
drawn on experience from previous coronavirus outbreaks.(4,5) 







Pregnancy and coronavirus disease-2019 (COVID-19) 
share several common features which makes differen-
tiation between the 2 diffi cult. Both are multisystem 
disorders, may present with breathlessness, are asso-
ciated with hypercoagulability and frequently cause 
signifi cant anxiety in both the patient and those around 
them. Pregnancy represents a state of partial immune 
suppression, with pregnant women more vulnerable to 
viral infections. However, these concerns have not been 
borne out in clinical practice and have not stood up to 
epidemiological scrutiny. From limited data available on 
COVID-19 in pregnancy, the outcomes are mostly 
favourable. While cardiac disease and hypertension are 
independent predictors of hospital admission with 
COVID-19 in pregnancy, the prevalence of cardiac 
disease in the pregnant COVID-19 population is low. 
Pregnant women are younger, and asymptomatic SARS-
CoV-2 infection and favourable outcomes are reported 
in those below 55 years of age. Indeed, large numbers of 
asymptomatic cases have been reported in pregnancy, 
suggesting that pregnant patients with more severe 
disease courses may be over-represented in the current 
literature, particularly the early case reports and 
case series. Cardiovascular involvement in pregnancy 
includes new-onset hypertension, myocarditis, cardio-
myopathy, pulmonary embolism and a pre-eclampsia-
like syndrome.  SAHeart 2020;17:288-295
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Chinese expert recommendations for the care of pregnant 
women with suspected and confirmed COVID-19 were 
developed and disseminated in China quite early following the 
outbreak in Wuhan,(6) and have been dynamic and evolving as 
more knowledge about epidemiology, pathogenesis, disease 
progression and clinical course among infected pregnant 
patients has been gathered. With thousands of pregnant 
women treated for COVID-19 and delivered in China, there 
have been no pregnancy-related deaths.(7,8) The Royal College 
of Obstetricians and Gynaecologists (RCOG), for example, 
classifies pregnant women as vulnerable, advising them to 
shield – incorporating guidance from the UK Maternal Cardiac 
Society – which states women with significant cardiovascular 
disease (CVD), congenital or acquired, should be treated as 
extremely vulnerable, based on expert consensus rather than 
evidence.(9) The South African National Department of Health 
has also promulgated guidance on COVID-19 and maternal 
care, which mandate that high risk women should be managed 
in a designated unit, but do not make specific reference to 
CVD.(10) While there have been many case reports and small 
case series, the scarcity of published data on pregnancy 
associated with COVID-19 has meant that guidance in many 
countries is based less on evidence and more on consensus 
opinion of experts and on data extrapolated from other 
respiratory viral infections.
At a time when health services were overwhelmed with 
COVID-19 cases globally, healthcare workers on the frontline 
experienced a new syndrome of covid-centricity, where breath-
lessness and hypoxia, including in pregnant women, is readily 
ascribed to COVID-19, risking cardiac decompensation in 
pregnancy from either pre-existing or new CVD being over-
looked, with potentially life-threatening consequences for 
mother and unborn baby.(9)
POTENTIAL RISKS OF COVID-19 
IN PREGNANCY
Hypertensive disorders of pregnancy, which include pre-
eclampsia and eclampsia, are the most common direct cause of 
maternal mortality and account for 18% of all maternal deaths 
in South Africa.(11) Pre-eclampsia is diagnosed in women 
presenting with a blood pressure of >140/90mmHg accom-
panied by proteinuria or the evidence of organ dysfunction 
after the 20th week of pregnancy.(11) Typical presentations of 
pre-eclampsia and eclampsia include headaches, seizures, loss 
of consciousness, haemolysis, elevated liver enzymes, thrombo-
cytopenia and renal dysfunction. Several disorders such as acute 
fatty liver of pregnancy, thrombotic thrombocytopenic purpura 
and haemolytic uremic syndrome have previously proved to 
imitate pre-eclampsia, because they share similar clinical and 
laboratory findings of patients with pre-eclampsia. An accurate 
diagnosis is important when caring for such patients, as the 
management and prognosis of these conditions differ widely. 
Although COVID-19 is primarily a respiratory infection, it has 
important systemic effects including hypertension, renal disease, 
thrombocytopenia and liver injury.(12) SARS-CoV-2 invades 
the host through cell entry via the receptor angiotensin-con-
verting enzyme 2 (ACE2), resulting in dysfunction of the 
renin-angiotensin-aldosterone system.(13) By contrast, pre-
eclampsia is the consequence of endothelial damage caused by 
placental oxidative stress and angiogenic imbalance. In a 
prospective observational study of 42 consecutive pregnancies, 
12% developed features of pre-eclampsia – all with severe 
presentations. However, abnormal angiogenic biomarkers and 
uterine artery pulsatility could only be demonstrated in one 
case, suggesting that severe COVID-19 infection among preg-
nant women may induce a pre-eclampsia-like syndrome.(12) 
Furthermore, a retrospective case series of hospitalised patients 
with COVID-19 showed that 36% of patients had neurological 
symptoms including headache, seizures and loss of conscious-
ness.(14) Low platelets and elevated liver enzymes have also 
been reported in patients with COVID-19, including those with 
acute cerebrovascular manifestations.(15) Women presenting 
with these overlapping clinical scenarios require an accurate 
diagnosis, because misdiagnosis and incorrect management 
have implications for pregnancy outcome and infection control 
practices. 
Changes in the coagulation system during pregnancy produce 
a physiological hypercoagulable state, in preparation for 
haemostasis following delivery. Concentrations of clotting 
factors, particularly factors VIII, IX and X, are increased. 
Fibrinogen levels rise significantly by up to 50% and fibrinolytic 
activity is decreased. Concentrations of endogenous anti-
coagulants such as antithrombin and protein S decrease. Thus, 
TABLE I: Abbreviations.
ACOG
American College of Obstetricians and 
Gynecologists
AHA American Heart Association
CDC Centers for Disease Control and Prevention
COVID-19 Coronavirus disease-2019
CVD Cardiovascular disease
MERS Middle East Respiratory Syndrome
SARS Severe Acute Respiratory Distress Syndrome
SARS-CoV-2
Severe Acute Respiratory Distress Syndrome 
Coronavirus-2
UKOSS United Kingdom Obstetric Surveillance System
WHO World Health Organization
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pregnancy alters the balance within the coagulation system in 
favour of clotting, predisposing the pregnant and postpartum 
woman to venous thrombosis. SARS-CoV-2 infection further 
increases the risk for thrombosis by causing the release of 
inflammatory cytokines that induce the production of tissue 
factor and activate thrombin and clot formation.(16) In non-
pregnant patients admitted to the intensive care with 
COVID-19 pneumonia, the frequency of venous thrombo-
embolic disorders was 25%,(17) but arterial and venous throm-
boembolism is described in 31% of those admitted with 
COVID-19 pneumonia.(18) Thrombotic complications such as 
ovarian vein thrombosis and pulmonary emboli have also 
been reported in pregnant women with COVID-19,(19,20) while 
the first COVID-19 maternal death reported in the United 
Kingdom was the result of pneumonia complicated by 
thrombosis.(21) The South African Framework and Guidelines 
for Maternal and Neonatal Care for COVID-19 recommend 
that low-molecular-weight heparin be considered for all women 
admitted to hospital with COVID-19.(10)
CURRENT STATE OF KNOWLEDGE ON 
COVID-19 AND PREGNANCY
Asymptomatic infection with SARS-CoV-2 appears to be 
common in pregnant women. After implementation of uni-
versal testing in 2 affiliated New York City hospitals, asymp-
tomatic infection of a third of pregnant women presenting to 
their maternity services was noted.(22) Seventy-one percent 
developed symptoms during their pregnancy, but 86% of all 
COVID-19 pregnant women exhibited only mild symptoms 
(Table II depicts severity scores for COVID-19). Nine percent 
had severe presentations and 5% critical disease; these 14% 
required hospital admission. Seventeen percent reported 
symptoms of chest pain, but no cardiac biomarkers were 
recorded, and no CVD was reported. Importantly, there were 
no deaths, and no vertical transmission occurred. Mean age was 
29 years and mean gestational age at diagnosis was 37 weeks. 
All caesarean sections were for obstetric reasons, none related 
to COVID-19 diagnosis. Neonatal outcomes were good.(22)
A small case series of 9 pregnant women (age range 26 - 40 
years) infected with SARS-CoV-2 in Wuhan, China, demon-
strated that the clinical characteristics of pregnant patients did 
not differ from non-pregnant patients.(7) All 9 had presented 
in the third trimester, had live births, and all women survived. 
The babies were delivered via caesarean section in good con-
dition beyond 36 weeks’ gestation. Cord blood, amniotic fluid 
and neonatal throat swabs were negative for the presence of 
the virus, and it was not detected in the breastmilk samples 
examined. In this small study, no vertical transmission was 
observed. None of the patients had pre-existing illnesses such 
as diabetes, hypertension or other CVD, and no cardiac 
symptoms or evidence of cardiovascular manifestations of 
COVID-19 were reported, although markers of cardiac injury 
such as serum troponin were not measured.(7) Similarly, Khan, 
et al. describe a series of 3 women (age range 27 - 33 years) 
with COVID-19 who delivered vaginally, 2 at term and 1 at 
34 weeks’ gestation. All patients and babies had good out-
comes, and no in utero or vertical transmission occurred.(23)
TABLE II: Classification of COVID-19 disease severity.
US National Institutes of Health classifi cation of disease severity(50) Wu classifi cation of disease severity(51)
Asymptomatic or 
pre-symptomatic infection 
Positive test for SARS-CoV-2, 
but no symptoms.
Mild No or mild symptoms (fever, fatigue, cough, 
and/or less common features of 
COVID-19).
Mild illness Any signs and symptoms (e.g. fever, cough, 
sore throat, malaise, headache, muscle pain) 
without shortness of breath, dyspnoea, or 
abnormal chest imaging.
Severe Tachypnoea (respiratory rate >30 breaths 
per minute), hypoxia (oxygen saturation 
≤93% on room air or PaO2/FiO2 
<300 mmHg), or >50% lung 
involvement on imaging).
Moderate illness Evidence of lower respiratory disease by 
clinical assessment or imaging and a 
saturation of oxygen (SaO2) >93% on room 
air at sea level.
Critical Respiratory failure, shock, or multiorgan 
dysfunction.
Severe illness Respiratory frequency >30 breaths per 
minute, SaO2 ≤93% on room air at sea level, 
ratio of arterial partial pressure of oxygen 
to fraction of inspired oxygen (PaO2/FiO2) 
<300, or lung infi ltrates >50%.














Recently, data on larger cohorts of pregnant patients with 
COVID-19 have become available. Pierce-Williams and col-
leagues have reported on 64 pregnant women hospitalised 
across 12 institutions with severe or critical SARS-CoV-2 
infection.(24) Of these, 17% had pre-existing cardiac disease, 
but none died, and none developed cardiomyopathy. One 
woman survived a cardiac arrest. Mean gestational age at 
hospitalisation in this study was low (30 weeks), and 75% were 
non-Caucasian, including Hispanic ethnicity. Preterm birth 
occurred in approximately 60%, with deliveries <34 weeks’ 
gestation more common in the critical disease cohort. The 
authors recommend iatrogenic preterm delivery in women 
with pre-existing disease to allow more aggressive treatment if 
the patient progresses to a critical disease stage and conclude 
that pregnancy itself should not be considered an independent 
predictor of a more severe disease course.(24)
The UK Obstetric Surveillance System (UKOSS) has published 
the largest cohort of COVID-19 patients who are pregnant and 
is the only population-based report. All 194 consultant-led 
maternity units in the UK participated, reporting on 427 preg-
nant women admitted with COVID-19 in a 6-week period 
between March and April 2020, against an estimated back-
ground of over 86 000 maternities in the same period, 
representing an incidence of 4.9 per 100 000 maternities.(25) 
Most admissions with COVID-19 occurred in the third tri-
mester (mean gestational age 34 weeks), with risk factors 
mirroring those seen in the general population, including older 
age. More than half of the patients were from Black and other 
non-Caucasian ethnic groups, with Black and Asian women 
mostly affected. Thirty-four percent had pre-existing medical 
conditions, of which only 1% had cardiac disease and 3% were 
hypertensive. No cardiac events are reported in this cohort. 
Nine percent required intensive care and 4 women required 
extracorporeal membrane oxygenation. Five women died, 
giving a case fatality rate or 1.2% and a maternal mortality of 
5.6 per 100 000 maternities. Ninety-two percent were dis-
charged well, with a further 7% still in hospital at the time of 
writing. Pregnancy loss was twice as common in the COVID-19 
cohort compared to a historic population. Seventy-four percent 
of women who gave birth during this time delivered at term, 
59% via caesarean section, of which only 27% had sections 
for maternal reasons. Five percent of neonates tested positive 
for SARS-CoV-2, and 2% had evident presence of viral RNA 
within twelve hours of birth, suggesting that vertical trans-
mission may be possible – although only rarely. Neonatal out-
comes, however, were reassuring.(25)
There appears to be some risk of premature rupture of 
membranes, preterm delivery, fetal tachycardia and fetal dis-
tress when SARS-CoV-2 infection occurs in the third trimester 
of pregnancy (Figure 1).(26,27) However, there is no evidence 
suggesting transplacental transmission based on limited data, 
as the analysis of amniotic fluid, cord blood, neonatal throat 
swab, and breast milk samples have all been found to be 
negative for SARS-COV-2. Whether virus shedding occurs 
vaginally is also not known. Whether COVID-19 increases the 
risk of stillbirth is unknown, though there has been no major 
signal to suggest such. There is a single case report of a 17-year-
old pregnant woman who had a second trimester miscarriage 
and the placenta was infected with SARS-CoV-2.(28) In general, 
there is a paucity of data on COVID-19 and the risk of mis-
carriage or congenital abnormalities associated with first and 
second trimester infections. COVID-19 is associated with a 
maternal pyrexia. This increase in core body temperature in the 
first and second trimester during the critical period of 
organogenesis raises the theoretical concern of congenital 
abnormalities, especially neural tube defects.(29) However, this 
theoretical concern has not been observed in clinical practice, 
and there is no definitive evidence of fetal transmission des-
cribed in the literature to date. Allotey, et al. also describe 
fewer pregnant women presenting with fever compared to the 
general population infected with SARS-CoV2.(27) Concerns 
have been expressed about women undergoing termination of 
pregnancy for fear of congenital infection and teratogenicity, 
but to date, no adverse outcomes have been reported in babies 
born to mothers infected with SARS-CoV2. Therefore, ter-
mination of pregnancy for fetal reasons does not appear to be 
indicated.(30) Information on effects of COVID-19 on course 
and outcome of pregnancy in the first and second trimesters is 
not yet available.
COMPARISON OF CURRENT KNOWLEDGE 
ON COVID-19 AND PREGNANCY TO HISTORIC 
KNOWLEDGE ON MERS AND SARS-COV 
AND PREGNANCY
A study of 12 pregnant women infected with SARS-CoV from 
Hong Kong reported high incidences of spontaneous mis-
carriage, preterm delivery, and intrauterine growth restriction, 
but no vertical transmission occurred.(31) No cardiac involve-
ment was described. Unlike with SARS-CoV-2 infection, preg-
nant women with SARS-CoV had worse outcomes than a 
comparable non-pregnant cohort, with a maternal death rate 
of 50%.(31)
A meta-analysis of pregnancy outcomes for MERS, SARS and 
SARS-CoV-2, reports on 79 pregnancies (52% with SARS-
CoV-2, 15% with MERS, 33% with SARS) and observed that 
intensive care admission, need for mechanical ventilation, and 
maternal death were significantly lower in COVID-19 compared 
to those infected with MERS and SARS.(32) In this meta-analysis, 
COVID-19 was associated with a higher rate of pre-eclampsia, 
preterm birth, preterm prelabour rupture of membranes, fetal 
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growth restriction, miscarriage and caesarean section. CVD is 
not mentioned in this study. They reported no vertical trans-
mission for either coronavirus types.(32) Another meta-analysis 
of coronavirus infection in pregnancy included 32 COVID-19 
cases, 2 of which required intensive care admission; however, 
SARS-CoV-2 was less lethal than other coronavirus infections 
(namely SARS and MERS).(33)
Placental pathology from 16 patients with SARS-CoV-2 
infection was compared with controls, with evidence of 
increased rate of maternal vascular malperfusion, most 
specifically decidual arteriopathy as well as a significant increase 
in intervillous thrombi.(34) Prior to COVID-19, the major 
maternal risk factor associated with these placental findings 
was pre-eclampsia.(35) These findings suggest possible mecha-
nisms for the observed adverse perinatal outcomes associated 
with COVID-19, and suggest that increased antenatal sur-
veillance is indicated in pregnant women diagnosed with 
COVID-19.
CURRENT STATE OF KNOWLEDGE ON 
COVID-19 AND PREGNANCY-RELATED 
CARDIOVASCULAR DISEASE
Viral myocarditis and cardiomyopathy have been reported in 
non-pregnant COVID-19 patients.(36,37) A case series of non-
pregnant COVID-19 patients demonstrated that 33% of 
those in intensive care developed cardiomyopathy.(36) A case 
series of the first 7 patients with COVID-19 in pregnancy in a 
US centre, showed that 2 of them developed a cardiomyopathy 
with moderately reduced left ventricular ejection fractions of 
40% - 45% and global hypokinesis (Figure 1).(38)
In addition, there is increasing evidence that pulmonary 
embolism is a complication of COVID-19 in non-pregnant 
individuals.(18) A case of pulmonary embolism in an obese, preg-
nant woman with COVID-19 has been published.(20) Obese 
pregnant women with COVID-19 may have a particularly high 
risk of pulmonary embolism because of coexisting prothrom-


























botic conditions and risk. Therefore, pregnant women with 
COVID-19 should be considered for tailored antithrombotic 
prophylaxis during pregnancy and in the puerperium (Table III).
MANAGEMENT OF THE PREGNANT WOMAN 
WITH COVID-19
The American College of Obstetricians and Gynecologists 
(ACOG),(39) the RCOG,(40) the Society for Maternal-Fetal 
Medicine,(41) the South African National Department of 
Health,(10) and others have promulgated guidelines on man-
agement of pregnancy during the COVID-19 pandemic. This 
guidance has focused on screening and testing, defining 
high-risk groups and tips for follow-up of the pregnant 
woman. Indications for and frequency of fetal testing are 
defined and include consideration of gestational age, stability 
of maternal vital signs, maternal oxygenation, and comor-
bidity. Implications for management of pregnant women with 
COVID-19 and CVD are summarised in Table III. 
Most pregnant women with COVID-19 have mild disease and 
do not necessarily warrant hospital-level care during preg-
nancy. Acute  respiratory distress syndrome (ARDS) and 
interstitial pneumonia are the causes of severe hypoxaemic 
respiratory failure critically ill patients. Complications of 
ARDS in COVID-19 include acute kidney, liver and cardiac 
injury. In pregnancy, maternal oxygen saturation should 
ideally be maintained at ≥95%.(42) While proning is impor-
tant for recruitment and improving oxygenation in critically 
ill patients, the left lateral position is an alternative but may 
not be as effective in pregnant women. Padding above and 
below the gravid uterus after 24 weeks is desirable to avoid 
aortocaval compression. There are limited data on extra-
corporeal membrane oxygenation for treatment of ARDS 
in pregnancy, and it does not appear to be harmful to the 
foetus.(43)
To date there have been 2 reports describing the increased 
admission to ICU and need for a ventilator among pregnant 
women compared to the non-pregnant population.(44,45) More 
research is needed in this area is, to assess the effect of 
comorbidities such as hypertension, diabetes, CVD and 
obesity with respect to short and long term maternal and 
fetal outcomes.  
Thromboembolic risk is increased in COVID-19,(46-48) there-
fore thromboprophylaxis should be initiated in all pregnant/
postpartum women with COVID-19 admitted to the hos-
pital. Studies are underway to assess treatment options for 
pregnant women with SARS-CoV-2 infection, but no results 
are available at the time of writing. 
TABLE III: Implications for management of pregnant patients with Covid-19 and cardiovascular disease.
Prevalence of cardiovascular disease is low in the pregnant cohort published to date.
Outcomes of COVID-19 in pregnant patients are generally reassuring.
Cardiovascular complications of COVID-19 in pregnant women are not reported in the literature.
The current lack of data on pregnant COVID-19 patients with CVD needs to be addressed, ideally with an international registry – e.g. through existing 
international obstetric surveillance programmes such as INOSS.
Pregnancy itself should not be considered a risk factor for COVID-19 disease severity.
Cardiovascular care for pregnant women with COVID-19 and CVD is no different to that of non-infected patients.
TABLE IV: Key take-home messages on COVID-19 and the cardiovascular system in pregnancy.
COVID-19 and pregnancy share many common clinical features.
Pregnancy represents a state of partial immune suppression, with pregnant women more vulnerable to viral infections and with higher morbidity and mortality 
from SARS, Zika and MERS.
Concerns of increased maternal mortality and morbidity have not been borne out in clinical practice and have not stood up to epidemiological scrutiny. 
From limited data available on COVID-19 in pregnancy, the outcomes are mostly favourable.
There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when SARS-CoV-2 infection 
occurs in the third trimester of pregnancy.
Cardiovascular involvement in pregnancy includes new-onset hypertension, myocarditis, cardiomyopathy, pulmonary embolism, and a 
pre-eclampsia-like syndrome.
Pregnant women are younger, and asymptomatic SARS-CoV-2 infection and favourable outcomes are reported in those below 55 years of age.
To date, no proven treatment for SARS-CoV2 infection, specifi cally for pregnant women, is available.
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CONCLUSION
COVID-19 and pregnancy share common features: both are 
multisystem disorders, may present with breathlessness, are 
associated with hypercoagulability and frequently cause signi-
ficant anxiety in both the patient and those around them. From 
limited data available on COVID-19 in pregnancy, the outcomes 
are mostly favourable (Table IV). While cardiac disease and 
hypertension are independent predictors of hospital admission 
with COVID-19 in pregnancy, the prevalence of cardiac disease 
in the pregnant COVID-19 population is low. Pregnant women 
are younger, and asymptomatic SARS-CoV-2 infection and 
favourable outcomes are reported in those below 55 years of 
age. Indeed, large numbers of asymptomatic cases have been 
reported in pregnancy, suggesting that pregnant patients with 
more severe disease courses may be overrepresented in the 
current literature, particularly the early case reports and case 
series. Further, findings of the UKOSS suggest good pregnancy 
outcomes in COVID-19, even in symptomatic patients. To 
date, no proven treatment for SARS-CoV2 infection, specifically 
for pregnant women, is available. 
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